On May 25, 2022, Novavax announced it was participating in a stage of the COVID-19 Vaccine Schedule Combinations (Com-COV) program initiated by the University of Oxford and supported by the UK Vaccine Taskforce and the National Institute for Health and Care Research. Novavax’ protein-based COVID-19 vaccine, NVX-CoV2373, was one of two COVID-19 vaccines studied as a third dose booster in adolescents aged 12 through 15 years to evaluate the potential use of vaccines from different manufacturers to achieve immune protection against COVID-19.